UNSPSC 51263130: Pacrinolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C23H28N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CHE211JZXQ, chemically known as (-)-p-(3-((3,4-dimethoxyphenetyl)amino)-2-hydroxypropoxy)-beta-methylcinnamonitrile but generally known as pacrinolol, which bears US NIH Compound Identifier 6436098. European Medicines Agency schedules Pacrinolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09584MIG.

UNSPSC 51263130 Pacrinolol is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and related health interventions—specifically naloxone, drug deactivation systems, and direct-to-manufacturer prescription fulfillment programs. The solicitations under this code show state and local health agencies procuring emergency pharmaceutical supplies and designing pharmacy benefit programs to improve cost management and prescription fulfillment efficiency. Issuing bodies include county health departments and state health and human services commissions. The work spans both routine commodity procurement (purchasing finished pharmaceutical products and medical supplies for inventory and distribution) and strategic program design (establishing direct contracting relationships between state pharmacy benefit programs and manufacturers to bypass intermediaries).

Recent activity concentrates in Florida and Texas. Seminole County, Florida issued an IFB (No. IFB60459723LAS, posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract includes a two-year initial term with one-year renewal option and requires E-Verify compliance, drug-free workplace certification, and specific insurance coverages. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013, posted April 3, 2026, due April 3, 2026) seeking vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers, designed to improve efficiency and cost management outside traditional pharmacy benefit manager and group purchasing organization arrangements.